Envista Holdings

Envista Holdings is the dental-products company that nobody pays attention to because the headline story (dental! premium-pricing! Chinese consumer slowdown!) sounds like exactly the kind of mid-cap consumer-discretionary that should be avoided in a wobbly macro. The closer look tells a different story: Envista is in the early stages of an operational turnaround under a new CEO, has put up earnings growth of 130% year-over-year, and trades at a forward P/E of 14.8x — meaningfully below dental-peer averages.

The business splits into two segments. Specialty Products and Technologies (approximately 60% of revenue) sells dental implants under the Nobel Biocare brand (the original premium implant system, still the global market leader by share), orthodontic brackets and clear aligners under Ormco, and biomaterials under Implant Direct. Equipment and Consumables (40% of revenue) sells imaging systems, treatment-center equipment and disposable consumables under the KaVo Kerr brand portfolio.

The turnaround story has three legs. First, the China weakness that hit Specialty Products in 2024 (premium implant volume down 20-25% as Chinese consumers traded down to local brands) has stabilized — recent quarters show flat-to-positive China volumes after volume-based-procurement adjustments. Second, the new CEO Paul Keel (hired from 3M in late 2024) has cut SG&A by approximately 8% in twelve months while protecting R&D, lifting operating margin from 6.2% in FY2024 to 9.9% currently with line-of-sight to 12-14% by FY2027. Third, the Nobel Biocare new-product cycle (N1 implant system, plus DEXIS digital imaging integration) is now visibly translating to share gains in North America and Europe.

Translation: this is a self-help turnaround story in a defensive end market with sticky customers, not a glamorous tech disruption. The boring kind of compounder.

Institutional ownership shows steady value-and-quality accumulation. Capital Group at 7.6% (Capital Research Global Investors specifically added through Q1/2026 as turnaround thesis crystallized), Wellington Management at 5.8%, Massachusetts Financial Services (MFS) at 4.4%. The passive base (Vanguard 11%, BlackRock 10%, State Street 5%) is the standard Russell 2000 component.

The most notable signal is the appointment of activist investor JANA Partners to the board in March 2026 with a 2.1% economic stake. JANA has a track record of pushing portfolio rationalization at dental-and-medical-device mid-caps (recall Henry Schein 2023, ICU Medical 2021). Their public 13D filing argues for either an outright sale of the Equipment and Consumables segment or a divestiture of the lower-margin imaging business to focus the company on Specialty Products. CEO Paul Keel has publicly acknowledged the strategic review.

Insider activity has been net-buying since the 2024 trough: CFO Howard Yu purchased 320 thousand USD between September 2024 and November 2025 at prices ranging from 17-23 USD. Two independent directors added a combined 280 thousand USD in the same window. Short interest sits at 6.49% of float — moderate, no organized bear thesis. Days-to-cover at 3.8 is low, reflecting balanced positioning rather than crowded shorts.

Envista is a multi-metric mid-cap dental name where trailing P/E (56.7x) and forward P/E (14.8x) tell very different stories. The 8x compression between trailing and forward is unusual and reflects (a) earnings growth recovery and (b) operational leverage acceleration. EV/EBITDA at 11.5x is below the dental-peer median of 14-16x (Henry Schein, Patterson Companies, Align Technology mid-range) and below the medical-device-distribution peer median of 13-15x. The cleanest valuation frame is EV/EBITDA: if Envista trades to the peer median of 14x on FY2027 consensus EBITDA of 580 million USD, market cap moves to approximately 6.4 billion USD — implying 70% upside.

Sum-of-the-parts adds the activist optionality. Specialty Products segment at 15x EBITDA (premium dental-implant peer set) = approximately 3.8 billion USD; Equipment and Consumables segment at 9x EBITDA (general medical-equipment peer set) = approximately 1.5 billion USD; net of 1.8 billion USD debt = approximately 3.5 billion USD enterprise value — almost identical to current 3.7 billion. The market is therefore paying fair value for the business as currently configured; the upside lever is JANA-driven strategic action that monetizes the Equipment and Consumables segment at a premium to its consolidated multiple.

Price-to-book at 1.23x is below the 5-year average of 1.6x — suggests room to rerate as ROE recovers from current 2.2% to a normalized 10-12%. Dividend yield 0% (the company does not pay a dividend); capital return is purely buybacks plus opportunistic M&A.

1. Q3 2026: JANA strategic review preliminary outcome — divestiture announcement window
2. Q4 2026: Nobel Biocare N1 implant European launch — first major new-product revenue contribution
3. January 2027: FY2027 guidance — first commitment to 13-14% operating margin path

Envista is the kind of name that I find personally interesting because it sits at the intersection of three good things: an early-cycle operational turnaround under a credible CEO, a credible activist with a track record, and a forward valuation that is reasonable on stand-alone fundamentals before any strategic-action upside. The boring part is that the path to the 30-35 USD range takes 18-24 months and requires patience through what may be a couple more weak China-revenue quarters.

My personal sizing for this kind of name is 2-3% of equity with a hard stop at 17 USD (below the 52-week low and the August 2024 panic level). The first add-on trigger is the Q3/2026 JANA strategic-review outcome — a divestiture announcement at 8x+ EBITDA would justify doubling the position. The second add-on trigger is Q4/2026 N1 implant European launch traction. If neither catalyst delivers by year-end 2026, the boring base case still pays out as the operational margin path executes — just slower. Target 30 USD as the central case, 38-42 USD on activist-action plus operational success. Not a glamorous trade — but the asymmetric distribution favors patience.